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Abstract  
Adoptive T-cell transfer is a potentially effective strategy for treating cancer and viral 
infections. However, previous studies of cancer immunotherapy have shown that T cells 
expanded in vitro fall into an exhausted state and, consequently, have limited 
therapeutic effect. One way to overcome this obstacle is to use induced pluripotent stem 
cells (iPSCs) as a cell source for making effector T cells. In recent years, there have 
been several reports on generating effector T cells suitable for adoptive immunotherapy. 
The reported findings suggest that by using iPSC technology, it may be possible to 
stably derive large numbers of juvenile memory T cells targeted to cancers or viruses. In 
this review, we describe a strategy for applying iPSC technology to immunotherapy and 




































































technologies can be applied clinically in the future.    
 
Introduction 
T cells play a central role in acquired immunity against pathogens. Since the 
identification of tumor-specific antigens and their epitopes in the 1990’s (1), substantial 
progress has been made in our understanding of T cell-mediated antitumor responses. 
From that understanding emerged adoptive cell transfer (ACT) therapy for cancer, 
which makes use of tumor-infiltrating lymphocytes (TILs) and has achieved some 
success. For example, Rosenberg’s group in National Cancer Institute reported that after 
lymphodepleting systemic chemotherapy, adoptive transfer of TILs induced clear and 
reproducible responses in nearly 50% of melanoma patients (2). Despite the therapeutic 
potential of TIL infusion therapy against cancer and chronic viral infections, there 
remain two important biological problems must be overcome (3-5). One is that cancer 
and viruses often hamper or escape T cell immunity by increasing regulatory T cell 
(Treg) counts, expressing one our more inhibitory molecules (e.g., PD-1L), or 
suppressing antigen presentation. This can be partially remedied by 
removing/remodeling the host immune system using chemoradiotherapy or newly 



































































problem relates to the quality of T cells expanded ex vivo. As currently performed, in 
vitro expansion for ACT induces T cells to differentiate into a late effector state and 
increase killer activity; however these cells then fall into an exhausted state and do not 
survive or proliferate in vivo after infusion. Consequently, they have little therapeutic 
effect (2,7). Optimization of the in vitro culture protocol may improve outcomes, but for 
now the problem remains to establish antigen-specific T cell clones that need repeated 
stimulation in long-term culture periods. 
To overcome that problem, the therapeutic potential of induced pluripotent cells 
(iPSCs) is drawing attention (8). iPSCs have the capacity for self-renewal while 
maintaining pluripotency and could potentially be a major cell source for induction of 
juvenile T cells suitable for ACT therapy. T cells recognize antigens via their T cell 
receptors (TCRs). Because TCR genes are irreversibly rearranged in the thymus during 
T cell maturation, iPSCs derived from T cells (T-iPSCs) retain the rearranged TCR 
genes of the original cell. It would therefore be expected that redifferentiating T-iPSCs 
derived from antigen-specific T cells would produce large numbers of juvenile 
antigen-specific T cells. In mouse, the therapeutic potential of this approach was 
successfully demonstrated through nuclear transplantation and subsequent in vivo 



































































Valpha14 NKT cell nuclei (9,10).  
Generation of iPSCs from T cells was initially difficult. But over the years several 
groups, including ours, have succeeded in using integrated viral vector systems to 
produce T-iPSCs from mouse and human polyclonal and antigen-specific T cells (11-16). 
This has enabled the potential of T-iPSCs as a cell source for ACT to be explored all 
around the world.      
 
Generation of rejuvenated antigen-specific T cells using T-iPSCs 
In 2013, a series of studies were reported on the establishment of T-iPSCs from 
antigen-specific cytotoxic T cells (CTLs) and redifferentiation of the T-iPSCs into 
functional CTLs (16,17). Two Japanese groups, including ours, each succeeded in using 
a Sendai viral vector to establish T-iPSCs, our group from a HIV nef protein-specific 
CTL clone and Kawamoto’s group from a melanoma MART-1 antigen-specific CTL 
clone. To differentiate T-iPSCs into CTLs, we employed an in vitro differentiation 
protocol entailing co-culture with C3H10T1/2 and Delta-like 1-expressing 
OP9(OP9-DL1) stromal cells. After 35-40 days of differentiation, we obtained CD3+ 
CD4+ CD8+ double-positive (DP) stage T cells. It is at this stage during physiological 



































































T-iPSC-derived DP cells, activation of Rag-1 and Rag-2, two genes related to 
recombination machinery, was observed, as was a reduction in the percentage of 
original antigen-specific cells. To create mature CD8 single-positive (SP) CTLs from 
T-iPSCs without TCR gene revision, it was necessary to artificially end the TCR-α 
rearrangement. TCR signaling via the peptide-major histocompatibility complex (MHC) 
during positive selection is known to downregulate RAG expression and prevent further 
rearrangement of TCR (19). In addition, stimulation using a anti-CD3 antibody is 
known to mimic TCR signals (20). Both our group and Kawamoto’s stimulated 
differentiated T-iPSCs on days 35-40 using anti-CD3 antibody or PHA and succeeded in 
producing CD8 SP cells. In our hands, redifferentiated CD8 SP cells recognized the 
same peptide on HIV antigen as the original CTLs, and immunological assays revealed 
that these cells exhibit normal cytolytic activity, INF-γ secretion and degranulation 
when stimulated by their target peptide. In addition, proliferation assays revealed that 
redifferentiated T-iPSCs had greater expansion potential and longer telomeres than the 
original cells, indicating CTLs can become “rejuvenated” by passing through the 
T-iPSC state. 
Clonal expansion of acquired immune cells is very useful for clinical application, 



































































passing them through T-iPSCs enables us to expand clinically applicable T cell clones 
stably and without limit, which could drive innovation in ACT therapy. 
Decades of research into cancer immunology have established that strong 
lymphocyte infiltration is associated with a good outcome in many types of tumors, 
including melanoma and head and neck, breast, renal, bladder, urotherial, ovarian, 
colorectal and pancreatic cancers, among others. This provides hope that ACT could 
become an effective therapy for numerous tumor types (21). At present, however, 
clinical trials of ACT are performed only in a few tumors, like melanoma. This is in part 
because of the difficulty of achieving proliferation of tumor-specific CTLs, which must 
differ radically depending on the immunogenicity of the tumor (22). A stable and 
unlimited supply of tumor-specific CTLs derived from T-iPSCs will facilitate research 
into ACT therapy for many types of cancer not treatable with immunotherapy at present.           
 
iPSC based expansion of Mucosal-associated invariant T  
In T cells there are some subsets of innate T cells as represented by natural killer T 
(NKT) cells other than acquired immune T cells. Mucosal associated invariant T 
(MAIT) cells belong to the innate T cells and are abundant in humans, representing up 



































































cells (PBMCs) were known to play a pivotal role in host defense against a wide range of 
bacterial and fungal infection including mycobacterium. Recently, Wakao et al reported 
generating T-iPSCs from human cord blood MAIT cells by using Sev vector and 
redifferentiated them into MAIT cells. Redifferentiated MAIT (re-MAIT) cells could 
produce various cytokines such as IFN-γ , TNF-α in the presence of bacteria-fed 
monocyte as original MAIT cells do. Infusion of re-MAIT cells into 
immunocompromised nice showed their antimycobacterial activity in vivo (23). 
 This result not only demonstrate the clinical potential of T-iPSCs derived innate T cells, 
but also show the possibility of T-iPSC technology as a device to explore the rare or 
difficult to culture T cell populations 
 
Combination of T-iPSC and CAR technology 
Genetic engineering of T cells to express chimeric antigen receptors (CARs) has 
recently emerged as a promising approach to rapidly generating tumor-targeted T cells 
endowed with enhanced antitumor properties (24). Most CARs utilize an 
antigen-derived antigen-binding motif to recognize their target (25). This enables them 
to recognize cell surface antigens with a higher affinity than TCRs and to function in an 



































































overcoming some tumor escape mechanisms. Recently clinical trials of CD19 
CAR-modified T cells demonstrated their efficient targeting of acute and chronic 
lymphoblastic leukemias (26-30). Moreover, promising results on the use T-iPSCs as a 
cell source for CAR-modified T cells were recently reported (31). By itself, use of CAR 
technology is a new and potentially problematic strategy, and severe adverse effects 
have been reported in several clinical trials. But although many aspects of this approach 
require improvement, the combination of iPSC and CAR technologies offers a 
promising avenue to the treatment of cancers.           
 
Discussion 
T-iPSCs possess great potential as a cell source for ACT therapy. Establishing T-iPSCs 
from a patient’s own antigen specific T lymphocytes and redifferentiating them for ACT 
therapy is an ideal way to tailor immunotherapy. But this strategy still has significant 
problems, including the time required and cost. For example, it takes at least 3 months 
to establish T-iPSCs and redifferentiate them into T cells, and establishing iPSCs for 
each patient may be too costly for routine use. One possible solution is to generate a 
T-iPSC bank for common combination of cancer antigen and HLA haplotypes (i.e 



































































allo-antigenic HLA expression through genomic modification (32,33). If such an 
antigen-HLA-identified T-iPSC bank could be established, then the dream of 
coordinating antigen-specific CTLs for timely ACT therapy based on T-iPSCs with 
matched HLA-type might come true. This banking concept would match well with 
CAR or exogenous TCR transduction technology to T-iPSC. 
 Increasing the efficiency of T-iPSC generation and redifferentiation, 
establishment of feeder-free culture systems for T cells, cost reduction, and many 
biological and technical challenges lie ahead. But if it were possible to achieve T-iPSCs 
as a cell source for ACT therapy, then the treatment of malignancies and chronic viral 
infections would be completely changed, and the impact on medicine would be 
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